Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 17 of 17 publications.

Salis F, Bertuletti S, Bonci T, Caruso M, Scott K, Alcock L, Buckley E, Gazit E, Hansen C, Schwickert L, Aminian K, Becker C, Brown P, Carsin AE, Caulfield B, Chiari L, D'Ascanio I, Del Din S, Eskofier BM, Garcia-Aymerich J, Hausdorff JM, Hume EC, Kirk C, Kluge F, Koch S, Kuederle A, Maetzler W, Mico-Amigo EM, Mueller A, Neatrour I, Paraschiv-Ionescu A, Palmerini L, Yarnall AJ, Rochester L, Sharrack B, Singleton D, Vereijken B, Vogiatzis I, Della Croce U, Mazza C, Cereatti A. A multi-sensor wearable system for the assessment of diseased gait in real-world conditions. Front Bioeng Biotechnol. 2023 Apr 21;11:1143248. doi: 10.3389/fbioe.2023.1143248

Davenport E, Zhou X, Wang J, Nunna S, Oberdhan D, Fernandes A, Mekahli D. Disease burden and disease progression of young adult patients with autosomal dominant polycystic kidney disease. Poster presented at the National Kidney Foundation 2023 Spring Clinical Meeting; April 11, 2023. Austin, TX. [abstract] Am J Kidney Dis. 2023 Apr 1; 81(4, Supple 1):S102. doi: 10.1053/j.ajkd.2023.01.349

Zhou X, Davenport EK, Ouyang J, Krasa H, Garbinsky D, Agarwal I, Oberdhan D. Population characteristics across a pooled database of multiple Autosomal Dominant Polycystic Kidney Disease (ADPKD) clinical studies. Poster presented at the 2020 National Kidney Foundation Spring Clinical Meeting; March 2020. New Orleans, LA. [abstract] Am J Kidney Dis. 2020 Apr; 75(4):663.

Mader G, Purser M, Mladsi D, Sanon M, Oberdhan D, Watnick T, Seliger S. Benefit of tolvaptan on time to End-stage Renal Disease (ESRD) for patients with rapidly progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD): a disease progression model. Poster presented at the 2020 National Kidney Foundation Spring Clinical Meeting; March 2020. New Orleans, LA. [abstract] Am J Kidney Dis. 2020 Apr; 75(4):603.

Butler AM, Layton JB, Dharnidharka VR, McGrath LJ. Correspondence: In reply to 'High-dose versus standard-dose influenza vaccine in hemodialysis patients'. Am J Kidney Dis. 2020 Mar;75(3):456-7. doi: 10.1053/j.ajkd.2019.11.002

Butler AM, Layton JB, Dharnidharka VR, Sahrmann J, Seamans MJ, Weber DJ, McGrath L. Comparative effectiveness of high-dose versus standard-dose influenza vaccine among patients receiving maintenance hemodialysis. Am J Kidney Dis. 2020 Jan;75(1):72-83. doi: 10.1053/j.ajkd.2019.05.018.

Assimon MM, Brookhart MA, Fine JP, Heiss G, Layton JB, Flythe JE. A comparative study of carvedilol versus metoprolol initiation and 1-year mortality among individuals receiving maintenance hemodialysis. Am J Kidney Dis. 2018 Sep;72(3):337-48. doi: 10.1053/j.ajkd.2018.02.350.

Davis AE, Mehrotra S, Friedewald J, Ladner D. Characteristics of a simulation model of the national kidney transplantation system. Poster presented at the 2013 Winter Simulation Conference: Simulation: Making Decisions in a Complex World; December 2013. [abstract] Ieee/Acm Trans Comput Biol Bioinform. 2013 Dec; p.2320-9.

Bradbury BD, Brookhart MA, Winkelmayer WC, Critchlow CW, Kilpatrick RD, Joffe MM, Feldman HI, Acquavella JF, Wang OH, Rothman KJ. Evolving statistical methods to facilitate evaluation of the causal association between erythropoiesis-stimulating agent dose and mortality in non-experimental research: strengths and limitations. Am J Kidney Dis. 2009 Sep 1;54(3):554-60.

Bradbury BD, Wang O, Critchlow CW, Rothman KJ, Heagerty P, Keen M, Acquavella JF. Relative mortality and epoetin alfa dose in hemodialysis patients - Reply. Am J Kidney Dis. 2008 May 1;51(5):865-6.

Simon D, Finkelstein F, Barber B, Matza L, Borker R, Malley K. Predictors of disease progression in subjects with stage 3 or 4 CKD. Poster presented at the National Kidney Foundation 2008 Spring Clinical Meeting; April 6, 2008. Dallas, TX. [abstract] Am J Kidney Dis. 2008 Apr; 51(4):PB1-PB27.

Bradbury BD, Wang O, Critchlow CW, Rothman KJ, Heagerty P, Keen M, Acquavella JF. Exploring relative mortality and epoetin alfa dose among hemodialysis patients. Am J Kidney Dis. 2008 Jan 1;51(1):62-70.

Belozeroff V, Borker R, Barber B, Pupim L, Hakin R. Trends in parathyroid hormone (PTH) in hemodialysis patients. Poster presented at the National Kidney Foundation 2007 Spring Clinical Meeting; April 10, 2007. Orlando, FL. [abstract] Am J Kidney Dis. 2007 Apr; 49(4):PB1-PB24.

Hoy T, Fisher M, Borker R, Barber B, Stolshek B, Goodman W. Adherence to K/DOQI guidelines for bone metabolism & disease in chronic kidney disease. Poster presented at the National Kidney Foundation 2007 Spring Clinical Meeting; April 10, 2007. Orlando, FL. [abstract] Am J Kidney Dis. 2007 Apr; 49(4):PB1-B24.

Doan QV, Dylan M, Griffiths R, Borker R, Barber B, Kim J, Dubois RW. Economic impact of cardiovascular disease and fractures in patients with ESRD. Poster presented at the National Kidney Foundation 2007 Spring Clinical Meeting; April 10, 2007. Orlando, FL. [abstract] Am J Kidney Dis. 2007 Apr; 49(4):PB1-B24.

Ray J, Borker R, Barber B, Valentine W, Belozeeroff V, Palmer A. Cost-effectiveness of treating patients with cinacalcet early versus delaying treatment with cinacalcet for secondary hyperparathyroidism in patients with ESRD. Poster presented at the National Kidney Foundation 2007 Spring Clinical Meeting; April 10, 2007. Orlando, FL. [abstract] Am J Kidney Dis. 2007 Apr; 49(4):PB1-B24.

Simon D, Finkelstein F, Barber B, Matza L, Borker R, Malley K. Comorbidity among patients with chronic kidney disease. Poster presented at the National Kidney Foundation 2007 Spring Clinical Meeting; April 10, 2007. Orlando, FL. [abstract] Am J Kidney Dis. 2007 Apr;.